Skip to the content
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
Menu
  • Our Company
    • Management Team
    • Board Members
    • Events
  • Our Approach
  • Partner
  • Careers
  • Resources
  • News
  • Contact
Menu
  • Contact

Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.

read more
Path 3
  • Scientific Publication
  • March 3, 2020

Bailey JA, et al. (2020) “Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.” Sci Rep. 10(1): 3952. doi: 10.1038/s41598-020-60551-z

Abstract

Vaccines based on Plasmodium falciparum apical membrane antigen 1 (AMA1) have failed due to extensive polymorphism in AMA1. To assess the strain-specificity of antibody responses to malaria infection and AMA1 vaccination, we designed protein and peptide microarrays representing hundreds of unique AMA1 variants. Following clinical malaria episodes, children had short-lived, sequence-independent increases in average whole-protein seroreactivity, as well as strain-specific responses to peptides representing diverse epitopes. Vaccination resulted in dramatically increased seroreactivity to all 263 AMA1 whole-protein variants. High-density peptide analysis revealed that vaccinated children had increases in seroreactivity to four distinct epitopes that exceeded responses to natural infection. A single amino acid change was critical to seroreactivity to peptides in a region of AMA1 associated with strain-specific vaccine efficacy. Antibody measurements using whole antigens may be biased towards conserved, immunodominant epitopes. Peptide microarrays may help to identify immunogenic epitopes, define correlates of vaccine protection, and measure strain-specific vaccine-induced antibodies.

PreviousNimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
NextHigh-Throughput Identification of MHC Class I Binding Peptides Using an Ultradense Peptide Array.
PreviousNimble Announces Collaboration with Genentech to Discover and Develop Novel Peptide-Based Therapeutics
NextHigh-Throughput Identification of MHC Class I Binding Peptides Using an Ultradense Peptide Array.
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact
  • Our Company
  • Our Approach
  • Partner
  • Careers
  • Resources
  • Contact

603 Science Dr
Madison, WI, USA 53711

LinkedIn
  • Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech
    Read More